Introduction
============

Osteosarcoma is the most common primary malignant tumor of bone that most commonly affects children, adolescents, and young adults, with a global incidence of approximately one to three cases per million annually [@B1], [@B2]. Surgical resection was the primary treatment before 1970. However, the survival of osteosarcoma patients treated with surgery alone is less than 20% [@B3]. The long-term survival rate was improved to 65-70% after the advent of multiagent chemotherapy regimens in the early 1970s, especially the combination of high-dose methotrexate, doxorubicin, and cisplatin (MAP) [@B4].

Osteosarcoma exhibits a predilection for the long bones near the metaphyseal growth plate and most commonly occurs in the distal femur (43%), proximal tibia (23%), or humerus (10%) [@B1], [@B2], [@B5]. The incidence is higher in adolescents of age 15-19, with eight to eleven cases per million annually, accounting for \>10% of all solid cancers [@B6]. The patients with localized osteosarcoma that respond to preoperative combination chemotherapy always show good prognosis [@B7]. However, the overall 5‑year survival rate for patients with metastatic or relapsed osteosarcoma has remained at about 20% over the past 30 years [@B8]. The lung is the most common site of osteosarcoma metastasis (more than 85% of cases), with bone the second most common site [@B5]. Thus, seeking specific targets for early diagnosis and effective treatment is necessary.

Although candidate oncogenes (e.g., *RUNX2*, *VEGFA*, *MDM2*, and *PRIM1*) [@B9]-[@B12] and tumor suppressors (e.g., *TP53*, *RB1*, and *PTEN*) [@B13]-[@B15] have been identified in human osteosarcoma, the search for common molecular therapeutic targets in osteosarcoma has been disappointing to date [@B2]. Current clinical trials are focused on targeting the bone microenvironment (mainly osteoclasts and bone seeking) [@B8], [@B16], receptor tyrosine kinases (including Kit, VEGFR, FGFR, PDGFR, HER2, and IGF1R) [@B17]-[@B19], intracellular signaling pathways (SRC, mTOR, RAF, Aurora kinase A, and histone deacetylase) [@B20], and immune system [@B21]-[@B23]. Mifamurtide as an innate immune stimulant has shown clinical promise in the treatment of osteosarcoma [@B22], [@B23]. However, the strategies that target the bone microenvironment and signaling pathways remain controversial. For example, the Hedgehog, Notch, and WNT pathways have been implicated in both osteosarcoma and normal bone development, and targeted therapy may be problematic for children.

Tumorigenicity is defined as the ability of cells to give rise to tumors. Tumorigenicity of osteosarcoma cell lines in nude mouse is an important method for candidate target and drug screening. However, the mechanism remains obscure. Herein, the tumorigenic genes in osteosarcoma cell lines were identified by bioinformatic analysis, and Hes related family bHLH transcription factor with YRPW motif 1 (*HEY1*) was identified as a key factor in tumorigenicity of osteosarcoma cells by subsequent experimental validation.

Methods
=======

Cell lines
----------

Six osteosarcoma cell lines were obtained from American Type Culture Collection (ATCC) (<https://www.atcc.org/>). SJSA-1 (also known as OSA, ATCC: CRL-2098) and U-2 OS (ATCC: HTB-96) were cultured in RPMI-1640 (Gibco, 11875-085) containing 10% fetal bovine serum (FBS) (Gibco, 1099-141); 143B (ATCC: CRL-8303), MlNNG/HOS Cl \#5 \[R-1059-D\] (ATCC: CRL-1547), and MG-63 (ATCC: CRL-1427) were cultured in minimum essential medium (MEM) (Gibco, 11095-080) containing 10% FBS; Saos-2 (ATCC: HTB-85) was cultured in McCoy\'s 5A (Gibco, 16600-082) containing 15% FBS. All cell lines were maintained at 37℃ with 5% CO~2~.

*In vivo* tumorigenicity
------------------------

Osteosarcoma cell lines MG-63, Saos-2, U-2 OS, 143B, MNNG/HOS, and SJSA-1 were used for xenograft transplantation in BALB/c nude mice according to a previous report [@B24]. Briefly, 1×10^6^ cells in 100 μL serum-free phosphate-buffered saline (PBS) were injected subcutaneously into each flank of locally bred BALB/c-nu mice (5 weeks old, female; five mice per group). The tumor size was measured every 5 days, and tumor volume was calculated by the formula (length×width×width)/2. For the highly tumorigenic cell lines, the experiments were stopped within a month. For the poorly tumorigenic cell lines, the experiments were stopped after 90 days.

Quantitative polymerase chain reaction (qPCR) analysis
------------------------------------------------------

Total cellular RNA was extracted from osteosarcoma cells or stable shRNA-expressing 143B cells (80-90% confluence) using TRIzol reagent (Invitrogen, 15596026). The RNA concentration was measured by the NanoDrop 2000 (Thermo Fisher Scientific, ND2000). The first-strand cDNA was synthesized from 2 μg of total RNA with random primers, and subsequent qPCR was performed using the GoTaq RT-qPCR kit (Promega, A6010). The experiment was carried out with the ViiA 7 Real-Time PCR System (Applied Biosystems, 4453534), and expression of mRNA was assessed based on the threshold cycle (Ct). The relative mRNA expression levels were calculated as 2-^\[(Ct\ of\ mRNA)-(Ct\ of\ *GAPDH*)\]^ after normalization to *GAPDH* expression. qPCR primer sequences (F, forward; R, reverse; 5′→3′) were as follows: *CYP26B1*-F: GTTCTGCCTCGGAGCTGATT, *CYP26B1*-R: CAACCCAATCCCCCTGACAA; *GP1BB* -F: AGACCACGTGGGACAGAACT, *GP1BB*-R: CAGGGTCTGGACCGCATTG; *IFI44*-F: TGGGAGCTGGACCCTGTAAA, *IFI44*-R: CCTCCCTTAGATTCCCTATTTGCT; *DDX10*-F: ATGTACTTGGAGCGGCCAAA, *DDX10*-R: CCCAGCCCATCTGTTGAAGT; *FOXA2*-F: CTTCAAGTGCGAGAAGCAGC, *FOXA2*-R: CCGAGTTGAGCCTGTGAGG; *HEY1*-F: AGTTAGGAGAGAGCCGCTGA, *HEY1*-R: TGTTGCTGGGGCTGGTAAAT; *GAPDH*-F: AGGTCGGAGTCAACGGATTT; *GAPDH*-R: ATGAAGGGGTCATTGATGGCA.

Virus production and transfection
---------------------------------

shRNAs targeting *HEY1* were cloned into the pLent-U6-RFP-Puro (Vigne, \#LT88024) vector. Targeting sequences were as follows: shRNA-Ctr: 5′-GCACCCAGUCCGCCCUGAGCAAA-3′; shHEY1-1: 5′-GCAGGAGGGAAAGGUUACUUU-3′; shHEY1-2: 5′-CCCAACUACAUCUUCCCAGAU-3′. The 293T cell line was used for lentivirus packaging. Briefly, a 10-cm dish of 4×10^6^ non-confluent 293T cells were co-transfected with recombinant pLent-U6-RFP-Puro (Vigene, LT88024), pMD2G (Addgene, \#12259), and psPAX2 (Addgene, \#12260) for knock-down (RNAi), and pLent-C-HA (Vigene, LT88007), pMD2G, and psPAX2 for overexpression. The lentivirus-containing supernatant was harvested after 48 h and used for the subsequent experiment.

Western blot analysis
---------------------

All cell lines were harvested at 80-90% confluence and then lysed in radioimmunoprecipitation assay (RIPA) buffer (Thermo Fisher Scientific, \#89901). Protein concentration was measured with a bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific, \#23225). Protein samples were resolved by 8-10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad, \#162-0117). The membrane was blocked in Tris-buffered saline (TBS) containing 0.05% Tween-20 (Amresco, 0777-1L) with 5% nonfat skim milk (BD, \#232100) for 1 h at room temperature, followed by overnight incubation with primary antibodies at 4°C. After three washes in TBS with Tween-20 (TBST), the membrane was incubated with horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h at room temperature. After three washes in TBST, the membrane was treated with the EZ-ECL kit (Biological Industries, \#20-500-120) and visualized using the Tanon-5200 multi-automatic chemiluminescence/fluorescence imaging analysis system (Tanon Science & Technology Inc). The following antibodies were used: anti-HEY1 (Abcam, ab154077), anti-β-actin (CST, \#3700), and secondary antibodies including anti-rabbit IgG, HRP-linked antibody (CST, \#7074) and anti-mouse IgG, HRP-linked antibody (CST, \#7076).

*In vivo* fluorescence imaging
------------------------------

Images of 143B cell-bearing mice were acquired using the Clairvivo OPT plus imaging system (SHIMADZU). Briefly, mice were anesthetized by 2% isoflurane gas for 5 min using the RC2 Anesthesia Machine (VetEquip). Then, postanesthetic mice were imaged under 530-nm laser irradiation at the experimental endpoint.

Microarray datasets
-------------------

The microarray datasets in this study were obtained from the Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>). Gene expression profiles (GSE36001 and GSE42352) were provided by Professor Leonardo A. Meza-Zepeda [@B25] and Professor Anne-Marie Cleton-Jansen [@B26], respectively. Both GSE36001 and GSE42352 contain the gene expression profiles of osteosarcoma cell lines MG-63, Saos-2, U-2 OS, 143B, MNNG/HOS, and SJSA-1 (or OSA). The Sanger software package (V1.0.8) (<https://shengxin.ren/softs/Sanger_V1.0.8.zip>) was used for volcano plot calculation and visualization.

Signaling pathway, biological process, and protein-protein interaction (PPI) network enrichment analyses
--------------------------------------------------------------------------------------------------------

For signaling pathway and biological process enrichment analyses, the high-expression group containing 138 genes and low-expression group containing 86 genes in highly tumorigenic osteosarcoma cell lines (143B, MNNG/HOS, and SJSA-1) as compared with poorly tumorigenic osteosarcoma cell lines (MG-63, Saos-2, and U-2 OS) were analyzed using a publicly accessible web-based platform: Enrichr (<http://amp.pharm.mssm.edu/Enrichr/>) [@B27], [@B28]. Signaling pathway enrichment analysis was performed by Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, while biological process enrichment analysis was performed by gene ontology (GO) analysis. For PPI network enrichment and gene function analyses, STRING (<https://string-db.org/>) was used.

Kaplan-Meier analysis
---------------------

Kaplan-Meier survival plots were generated using the R2: Genomics Analysis and Visualization Platform (<http://r2.amc.nl>). Briefly, osteosarcoma patients were divided into two groups based on the expression value of indicated genes, and the survival rate between the two groups was tested via log-rank test with P-value\<0.05 considered significant.

Statistical analysis
--------------------

All data were analyzed with GraphPad Prism 6 software and are provided as the mean ± standard error of the mean (SEM) unless otherwise indicated. Statistical analyses were performed using an unpaired Student\'s t-test. P\<0.05 was considered to indicate statistical significance.

Results
=======

Tumorigenicity assay of human osteosarcoma cell lines
-----------------------------------------------------

Six osteosarcoma cell lines (MG-63, Saos-2, U-2 OS, 143B, MNNG/HOS, and SJSA-1) were used for tumorigenicity testing in BALB/c nude mice. At 30 days, all five mice formed tumors with 143B, MNNG/HOS, and SJSA-1cells, while none of the five mice formed tumors with MG-63, Saos-2, or U-2 OS cells (Figure [1](#F1){ref-type="fig"}A). The 143B, MNNG/HOS, and SJSA-1 cell lines formed tumors very rapidly, reaching a volume of \~1,000 mm^3^ within 30 days. In addition, MNNG/HOS showed the highest tumorigenicity compared with 143B and SJSA-1 (Figure [1](#F1){ref-type="fig"}B).

GEO and PPI analyses
--------------------

According to the tumorigenicity assay, the six osteosarcoma cell lines were divided into the highly tumorigenic group (143B, MNNG/HOS, and SJSA-1) and lowly tumorigenic group (MG-63, Saos-2, and U-2 OS). GEO datasets (GSE36001 and GSE42352) were analyzed with the GEO2R online tool. We set the threshold as P-value\<0.05 and log2 fold change (FC)\>1. Compared with the lowly tumorigenic group, 106 and 106 lowly expressed genes and 177 and 159 highly expressed genes were identified from GSE36001 and GSE42352, respectively, in the highly tumorigenic group (Figure [2](#F2){ref-type="fig"}A & B, [Table S1](#SM0){ref-type="supplementary-material"}). By combining GSE36001 and GSE42352, 86 lowly expressed genes and 138 highly expressed genes were identified (Figure [2](#F2){ref-type="fig"}C & D, [Table S1](#SM0){ref-type="supplementary-material"}). PPI analysis showed that 53 of 86 lowly expressed genes ([Figure S1](#SM0){ref-type="supplementary-material"}) and 89 of 137 highly expressed genes ([Figure S2](#SM0){ref-type="supplementary-material"}) were not included in the main PPI network, although the PPI enrichment P-value = 1.67e-05 for lowly expressed genes and 0.00961 for highly expressed genes. The low physical protein-protein interaction of these genes suggested that tumorigenicity involves various biological processes.

Signaling pathway (KEGG) and biological process (GO) enrichment analyses
------------------------------------------------------------------------

Eighty-six lowly expressed genes and 138 highly expressed genes were subjected to further KEGG and GO pathway analysis via Enrichr. The KEGG enrichment analysis revealed that lowly expressed genes were largely correlated with cell cycle, DNA replication and repair, virus infection, and various cancers (Figure [3](#F3){ref-type="fig"}A), whereas highly expressed genes were correlated with amino acid metabolism and glucose metabolism (Figure [3](#F3){ref-type="fig"}B). The GO enrichment analysis showed that lowly expressed genes corresponded with positive regulation of extracellular matrix assembly and response to DNA damage stimulus and negative regulation of mitochondrial outer membrane permeabilization, cell proliferation, and growth (Figure [3](#F3){ref-type="fig"}C); highly expressed genes corresponded with response to endoplasmic reticulum (ER) stress, aggrephagy, positive regulation of adaptive immune response, and amino sugar metabolic process (Figure [3](#F3){ref-type="fig"}D).

Identification of candidate lowly expressed and highly expressed genes
----------------------------------------------------------------------

Because of the low relevance of differentially expressed genes, further enrichment analysis was performed. For highly expressed genes, we set the threshold as P-value\<0.01 and log2FC\>2, and for lowly expressed genes, we set the threshold as P-value\<0.005 and log2FC\>2. Six lowly expressed genes (*CRIP2*, *CYP26B1*, *DPYSL4*, *GP1BB*, *IFI44*, and *PALLD*) and 6 highly expressed genes (*ARHGDIB*, *DDX10*, *DUSP5*, *FOXA2*, *HEY1*, and *TRIB3*) were identified (Figure [4](#F4){ref-type="fig"}A-D). However, the functions of these genes were quite different according to the PPI analysis (PPI enrichment P-value = 1) (Figure [4](#F4){ref-type="fig"}E & F). Of note, *HEY1* had an extremely low P-value in both GSE36001 and GSE42352.

Prognostic analysis and qPCR validation
---------------------------------------

Based on the candidate lowly expressed and highly expressed genes, the R2 Genomics Platform was used for prognostic analysis. High expression of *CYP26B1*, *GP1BB*, and *IFI44* in osteosarcoma patients was correlated with good prognosis (Figure [5](#F5){ref-type="fig"}A-C), while high expression of *DDX10* and *FOXA2* in osteosarcoma patients was associated with poor prognosis (Figure [5](#F5){ref-type="fig"}D & E). Notably, high expression of *HEY1* corresponded with poor prognosis (both overall survival and metastasis-free survival) (Figure [5](#F5){ref-type="fig"}F & G). qPCR confirmed that the expression changes were consistent with the microarray datasets (Figure [5](#F5){ref-type="fig"}H).

Importance of HEY1 in the tumorigenicity of 143B osteosarcoma cells
-------------------------------------------------------------------

The protein expression level of HEY1 detected by western blot was consistent with the mRNA level in osteosarcoma cell lines (Figure [6](#F6){ref-type="fig"}A). Western blot analysis of changes in HEY1 expression showed that shHEY1-2 is more effective (Figure [6](#F6){ref-type="fig"}B) under an equivalent infection rate (Figure [6](#F6){ref-type="fig"}C). The 143B osteosarcoma cells with red fluorescent protein (mStrawberry) were visualized under visible light (Figure [6](#F6){ref-type="fig"}D) to monitor cell growth (Figure [6](#F6){ref-type="fig"}E). The appearance of subcutaneous tumors at the experimental endpoint (Figure [6](#F6){ref-type="fig"}E & F), tumor growth curves (Figure [6](#F6){ref-type="fig"}G), and tumor weight (Figure [6](#F6){ref-type="fig"}H) showed that knockdown of HEY1 mRNA inhibited the tumorigenicity significantly. On the other hand, overexpression of HEY1 in a non-tumorigenic cell line Saos-2 (Figure [6](#F6){ref-type="fig"}I) could help Saos-2 cells to obtain the tumorigenicity (Figure [6](#F6){ref-type="fig"}J-M). These results revealed that *HEY1* is a key factor in the tumorigenicity of 143B osteosarcoma cells.

Discussion
==========

Identifying the tumorigenicity-associated genes in osteosarcoma is a valuable method for investigation of tumorigenic mechanisms. In this study, we evaluated the tumor-forming ability of six osteosarcoma cell lines. Three (143B, MNNG/HOS, and SJSA-1) were found to be tumorigenic, while the other three cell lines (MG-63, Saos-2, and U-2 OS) lacked tumorigenicity (Figure [1](#F1){ref-type="fig"}A). Thus, 143B, MNNG/HOS, and SJSA-1 were defined as the highly tumorigenic group, while MG-63, Saos-2, and U-2 OS were defined as the poorly tumorigenic group. Two microarray datasets from two independent studies containing the mRNA expression data of these six cell lines were used for analysis of differentially expressed genes.

It is generally accepted that the genes that promote cell cycle progression and DNA replication act as positive factors in tumorigenesis [@B29]. However, tumorigenicity is not always correlated with tumorigenesis or proliferation. The poorly tumorigenic MG-63 and U-2 OS cells showed the same proliferation rate as the highly tumorigenic 143B and SJSA-1 cells [@B24]. KEGG analysis showed that the cell cycle- and DNA replication-related genes were lowly expressed in the highly tumorigenic group, while amino acid metabolism- and glucose metabolism- related genes were highly expressed in the highly tumorigenic group (Figure [3](#F3){ref-type="fig"}A & B). Thus, we speculate that amino acid- and energy metabolism- associated genes are important to the tumorigenicity. In contrast, vigorous metabolism may help the osteosarcoma cells adapt to the environmental alteration [@B30]. Coincidentally, GO analysis showed that the intrinsic apoptosis- and aggrephagy-related genes were highly expressed in the highly tumorigenic group. It may help osteosarcoma cells overcome the temporary nutrition deficiency and adapt to the bioenergetic challenges *in vivo* [@B31], [@B32].

PPI analysis showed low relevance among the differentially expressed genes, which suggests that tumorigenicity is a complicated process involving various genes and biological pathways. Additional enrichment analysis identified six lowly expressed and six highly expressed genes. Nonetheless, there was no relevance among these differentially expressed genes. Half of these differentially expressed genes were correlated with good or poor prognosis. Indeed, one of the shortcomings of prognosis analysis for rare pediatric tumors, such as this study, is the lack of adequate samples to power the discovery of rare events.

We noticed that *HEY1* was highly expressed in the highly tumorigenic group with an extremely low P-value in both GSE36001 and GSE42352. In addition, the expression level of *HEY1* was positively correlated with the tumorigenicity of osteosarcoma cell lines. Thus, *HEY1* was selected for further investigation. In fact, *HEY1* is a candidate oncogene that is highly expressed in glioblastoma [@B33], [@B34], rhabdomyosarcoma [@B35], hepatocellular carcinoma [@B36], head and neck squamous cell carcinoma [@B37], and renal cell carcinoma [@B38], among other cancers. It is also associated with poor prognosis in head and neck squamous cell carcinoma [@B37] and esophageal squamous cell carcinoma [@B39]. On the other hand, *HEY1* acts a target gene of Delta-like canonical Notch ligand 4 (Dll4)-induced Notch signaling pathway activation and functions as an inhibitor of myogenesis [@B40]. Our data also proved that *HEY1* is a key factor involved in the tumorigenicity of osteosarcoma cells. We anticipate that this result will promote preclinical studies on this malignant tumor.

In summary, amino acid- and energy metabolism-associated genes are important to the tumorigenicity of osteosarcoma cells. Limited cell cycle progression and high level of amino acids and energy metabolism as well as aggrephagy may help osteosarcoma cells overcome the temporary nutrition deficiency and survive *in vivo*. Furthermore, *HEY1* is a key factor in the tumorigenicity of osteosarcoma cells. These results provide not only a new perspective to understand the mechanism of tumorigenicity but also another strategy for preclinical studies and targeted therapy of this orphan disease.
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![Tumorigenicity assay of human osteosarcoma cell lines. **(A)** Tumorigenicity of six osteosarcoma cell lines (MG-63, Saos-2, U-2 OS, 143B, MNNG/HOS, and SJSA-1) *in vivo*. **(B)** Tumor growth curve based on tumor volume (\*P\<0.05, n.s.: no significant by two-way ANOVA).](jcav11p3623g001){#F1}

![GEO analysis of differentially expressed genes. **(A)** & **(B)** Volcano plot of differentially expressed genes based on GSE36001 and GSE42352, respectively. **(C)** Differentially lowly expressed genes. **(D)** Differentially highly expressed genes.](jcav11p3623g002){#F2}

![Signaling pathway (KEGG) and biological process (GO) enrichment analyses. **(A)** KEGG analysis of differentially lowly expressed genes. **(B)** KEGG analysis of differentially highly expressed genes. **(C)** GO analysis of differentially lowly expressed genes. **(D)** GO analysis of differentially highly expressed genes.](jcav11p3623g003){#F3}

![Identification of candidate lowly expressed and highly expressed genes. **(A)** & **(B)** Volcano plot of candidate lowly expressed and highly expressed genes. **(C)** & **(D)** Lowly and highly expressed genes. **e** Function enrichment of lowly expressed genes. **f** Function enrichment of highly expressed genes. Log2 FC: Log2 fold change; FDR: False discovery rate.](jcav11p3623g004){#F4}

![Prognostic analysis and qPCR validation. Overall survival analysis of *CYP26B1* **(A)**, *GP1BB* **(B)**, *IFI44* **(C)**, *DDX10* **(D)**, *FOXA2* **(E)** and *HEY1* **(F)**. **(G)** Metastasis-free survival of*HEY1*. **(H)** qPCR validation of identification of candidate lowly expressed and highly expressed genes. (\*\*\*P\<0.001 by student\'s t-test).](jcav11p3623g005){#F5}

![HEY1 is a key factor in the tumorigenicity of 143B osteosarcoma cells. **(A)** Protein expression level of HEY1 in six osteosarcoma cell lines (MG-63, Saos-2, U-2 OS, MNNG/HOS, 143B, and SJSA-1). **(B)** Protein expression level of HEY1 after lentivirus-mediated RNA interference in 143B osteosarcoma cells. **(C)** Lentivirus infection efficiency detected by fluorescence microscopy (scale bar = 200 μm). **(D)** Lentivirus-infected 143B osteosarcoma cell pellet under visible light. **(E)** Images of 143B cell-bearing mice under 530-nm laser irradiation at the experimental endpoint. Subcutaneous tumors at the experimental endpoint **(F)**, tumor growth curves **(G)**, and tumor weight **(H)** are shown. **(I)** Protein expression level of HEY1 in Saos-2 and HEY1-overexpressed Saos-2 cells. **(J)** Tumorigenicity assay of Saos-2 cells after HEY1-overexpression. Subcutaneous tumors at the experimental endpoint **(K)**, tumor growth curves **(L)**, and tumor weight **(M)** of Saos-2 cells after HEY1-overexpression are shown.](jcav11p3623g006){#F6}
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